74 Chapter 5 Table 3: HMB treatment in women aged 18-30 years. HMB Treatment (n=27) self-BAT <5 n=6 n (%) self-BAT ≥5 n=21 n (%) OR (95% CI) P -value Medical: Hormonal 2 (33) 12 (57) 2.7 (0.4;17.9) 0.31 TXA 1 (17) 3 (14) 0.8 (0.1;9.9) 0.89 Hormonal + TXA 3 (50) 2 (10) 0.1 (0.0;0.9) 0.04 Iron 0 (0) 2 (10) 1.7 (0.1;39.4) 0.75 Surgery: EA 0 (0) 1 (5) 1.0 (0.0;26.3) 0.98 EA + hormonal treatment 0 (0) 0 (0) 0.3 (0.0-16.8) 0.58 Hysterectomy (incl. hysterectomy after EA) 0 (0) 2 (10) 1.7 (0.1-39.4) 0.75 Legend: OR, Odds ratio; TXA; tranexamic acid, EA; endometrial ablation, *OR reference groups: self-BAT <5 versus self-BAT ≥5. Table 4: HMB treatment in women aged 31-52 years. HMB Treatment (N=204) self-BAT <6 n=80 n (total %) self-BAT ≥6 n=124 n (total %) OR* (95% CI) P -value Medical: Hormonal 20 (25) 34 (27) 1.1 (0.6;2.2) 0.70 TXA 4 (5) 8 (6) 1.3 (0.4;4.5) 0.67 Hormonal + TXA 2 (3) 5 (4) 1.6 (0.3;8.7) 0.56 Iron 12 (15) 22 (18) 1.2 (0.6;2.6) 0.61 Surgery: EA 35 (44) 49 (40) 0.8 (0.5;1.5) 0.55 EA + hormonal treatment 4 (5) 3 (2) 0.5 (0.1;2.2) 0.97 Hysterectomy (incl. hysterectomy after EA) 3 (4) 18 (15) 4.3 (1.2;15.3) 0.02 Legend: OR, Odds ratio; TXA; tranexamic acid, EA; endometrial ablation, *OR reference groups: self-BAT <6 versus self-BAT ≥6. Respondents’ views on HMB management Of the participants, 44% (101/231) provided their reflection in the free-text section of the questionnaire. Most reflections consisted one of the following items: use of the self-BAT, awareness of the impact of heavy blood loss, and the need for patient empowerment. Some
RkJQdWJsaXNoZXIy MTk4NDMw